Filing Details

Accession Number:
0001140361-17-035899
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-19 15:17:52
Reporting Period:
2017-09-15
Accepted Time:
2017-09-19 15:17:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197355 J Henry Fuchs C/O Biomarin Pharmaceutical Inc.
770 Lindaro St.
San Rafael CA 94901
President, Worldwide R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-09-15 5,000 $26.49 141,422 No 4 M Direct
Common Stock Acquisiton 2017-09-15 10,000 $37.46 151,422 No 4 M Direct
Common Stock Disposition 2017-09-15 15,000 $90.50 136,422 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Common Stock Disposition 2017-09-15 5,000 $0.00 5,000 $26.49
Common Stock Stock Option (right to buy) Common Stock Disposition 2017-09-15 10,000 $0.00 10,000 $37.46
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,225 2011-11-12 2021-05-11 No 4 M Direct
37,934 2012-11-08 2022-05-07 No 4 M Direct
Footnotes
  1. Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.
  2. The price in column 4 is the weighted average price. The price actually received ranged from $89.26 to $91.89. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
  3. Reflects the number of options outstanding after the transactions from this specific stock option grant.